A few days ago, the "Clove Doctor" public issue released "A year of 750 million brainwashing medicines, please let go of the Chinese elderly" article, spearhead pointed to Shapu Aisi eye drops with brainwashing advertising marketing misleading the elderly , delay cataract treatment. The article spread rapidly on the Internet, dragging the "Sharp Aisi Eye Drops" into the whirlpool of public questioning, causing a nearly one-sided criticism.
In the A-share market, Shapu Aisi also suspended trading yesterday (December 7) on the grounds that “there are important announcements not announced†after four consecutive days of decline. The date of the resumption of trading was undecided.
In the voice of doubt, Qianjiang Evening News reporter rushed to Pinghu, Zhejiang, Zhejiang Shapu Aisi Pharmaceutical Co., Ltd. headquarters is located in Xinming Road, the local economic development zone. The reporter saw that the company was in a calm state, and production did not seem to be affected by the questioning. Even the company was still hiring employees that day.
For her, the success of the interview is much more important than whether Shapus Eye Drops can cure cataracts.
On-site: The company produces everything as usual
After a new turn to the right, not far from the headquarters of Shapu Aisi's several buildings, the factory is not new, but neat, clean, very conspicuous compared with the more common bags and packaging companies. .
On the right side of the main entrance, there is a “Regulations on Standardizing Employee Vehicle Parkingâ€, which requires “one person, one parking space, parked by numberâ€, and the parking space number is up to 203. According to the data, there are about 700 employees in Shapu Aisi, and these 203 parking spaces are obviously not enough. Therefore, the “East Road on the Factory Site†is also classified as a parking area. From these parked vehicles, at least the attendance rate of Shapu Aisi employees has not been affected by this incident.
"It doesn't matter, it's still the same as usual." Speaking of the widespread doubts that Shapu Aisi has been in these days, the staff of Shapu Aisi is very calm.
"(Company) said that there may be reporters coming over these two days, but no one actually came." The security guards at the door saw some curiosity from the reporters of Qianjiang Evening News. After repeatedly confirming their identity, they laughed and said, "You are the first." (a reporter who came.)"
On the same day, there were operations, technical, administrative and other positions in the recruitment. From time to time, candidates who came to the interview were registered in the guard room. Some of them knew about the incident, and some did not care.
“I came to apply for an administrative job.†A girl who came to the interview was in a hurry. For her, the interview was successful, which is much more important than whether Shapu Aisi Eye Drops can cure cataracts.
Occasionally, I met the employees of Shapu Aisi. They talked about the colder weather, talked about the lunch in the cafeteria, and talked about the courier that was just sent. The questioning that caused the medical community and public opinion attention did not appear in their conversation.
Response: Company Secretary secretly said that internal review is under way
According to the usual practice, the company has problems, and the relevant person in charge is always out of the scene. This time is no exception. Wu Jianguo, deputy general manager and secretary-general of Shapu Aisi, who is responsible for external disclosure of information and management of investor relations, said that he is not currently in Zhejiang: "The company is conducting internal review. There is no news for public release. All the company announcements are subject to change."
When will the new announcement be released? "Not sure, it depends on when the review is over." Wu Jianguo said to the media that Shapu Aisi Eye Drops is conducting a consistent evaluation. Yesterday, his reply to the reporter of Qianjiang Evening News was also a consensus evaluation. in conclusion".
Has Sharpe encountered similar incidents before this question was questioned? Wu Jianguo was silent for a while on the phone and said, "I have already answered the question you are most concerned about." Then he hanged up the phone because of too many things and too busy.
Other relevant personnel at the company's headquarters refused to appear, and the reasons were very consistent: there was something on hand, but it was too busy.
Provincial Food and Drug Administration requires Shapu Aisi
Start the test as soon as possible and check the ad immediately
On the afternoon of December 6, the State Food and Drug Administration issued an urgent notice, in view of the fact that some doctors in the medical profession have produced benzyl lysine eye drops for Zhejiang Shapu Aisi Pharmaceutical Co., Ltd. (trade name: Shapu love) Questioning the efficacy of the solution, requesting the Zhejiang Food and Drug Administration to urge the enterprise to start the clinical effectiveness test as soon as possible and in accordance with the relevant provisions of the Drug Administration Law of the People's Republic of China and the consistency evaluation of the quality and efficacy of generic drugs. The evaluation results were reported to the Drug Evaluation Center of the State Food and Drug Administration.
In the notice, the Food and Drug Administration requested that in order to prevent misleading consumers, the advertisements approved by Shapu Aisi Medicine should be strictly in accordance with the texts specified in the indications of the instructions, and there should be no text beyond the indications of the instructions.
At noon on December 7, the Zhejiang Food and Drug Administration issued the Notice on Forwarding the Relevant Matters Concerning Sharpe Eye Drops by the State Food and Drug Administration.
In this notice, the provincial food and drug supervision required Zhejiang Shapu Aisi Pharmaceutical Co., Ltd. to start the clinical effectiveness test as soon as possible; immediately conduct self-inspection of the advertisement; strictly implement the drug GMP (Good Manufacturing Practice) and GSP (Pharmaceutical Management) Quality management practices) to ensure the quality and safety of the drug's life cycle. Our reporter Zhang Miao
"Shapu Aisi" storm
On December 2nd, the well-known health management platform "Clove Doctor" published an article titled "A year of 750 million brainwashing medicines, please let go of the Chinese elderly", exploding the circle of friends, the article pointed to Shapu Aisi Eye drops. According to the article, Shapu Aisi's advertising costs in 2016 were as high as 260 million yuan, while drug research and development expenses were only 0.29 billion. In the advertisement, Shapu Aisi Eye Drops deliberately obscured the indication of "early senileness" in "early senile cataract" and replaced the disease name with symptoms to mislead patients.
Subsequently, some media reported that the cost of the product was only 1.45 yuan, but it was to sell a bottle of 43.5 yuan. In 2016, gross profit was as high as 94.49%.
On December 4th, Zhejiang Shapu Aisi Pharmaceutical Co., Ltd. issued a clarification announcement stating that Shapu Aisi Eye Drops is a safe and effective anti-cataract drug. The video advertisement content also complies with the relevant provisions of the Advertising Law. After examination and approval by the Zhejiang Food and Drug Administration, the relevant drug advertisement approval number has been obtained.
Since then, there have been media reports that Shapu Aisi advertising has also been controversial. In November 2012, the Changsha Drug Distribution Industry Association said that seven products, such as "Sharp Aisi", were suspected of violating the relevant provisions of the "Measures for the Examination of Pharmaceutical Advertisements."
On December 6, the State Food and Drug Administration issued a notice to the Zhejiang Food and Drug Administration on matters related to Shapu Aisi Eye Drops, requesting that “supervising enterprises to start clinical effectiveness experiments as soon as possible and reporting the evaluation results within three years. The Drug Evaluation Center of the State Food and Drug Administration has re-emphasized that the drug advertisement should be strictly in accordance with the texts specified in the indications of the instructions.
On the evening of the 6th, the listed company Shapu Aisi issued a notice saying that it was suspended due to unannounced important matters, and it was suspended all day on December 7.
On the morning of December 7, the Zhejiang Food and Drug Administration said that it would forward the notice of the State Food and Drug Administration to Shapu Aisi Company, and requested the company to immediately conduct self-inspection of advertisements and immediately correct it if it did not meet the requirements. (Qianjiang Evening News)
Smart Fire Protection System,Fire Alarm System Transmission Device,Fire System Protocol Converter,Protocol Converter Fire Device
LIAONING YINGKOU TIANCHENG FIRE PROTECTION EQUIPMENT CO.,LTD , https://www.tcfiretech.com